Lilly’s Donanemab Slows Cognitive Decline; FDA Filing Imminent
Full Approval Sought After Accelerated Nod Denied Previously
Executive Summary
The company’s anti-amyloid antibody succeeded in Phase III with efficacy at least on par with Eisai/Biogen’s Leqembi, but with ARIA-related deaths unseen with the rival therapy.
You may also be interested in...
Why Protein Misfolding Diseases Have Been Pharma’s Achilles Heel
Protein misfolding diseases, such as Alzheimer’s, are still largely untreatable and incurable. A leading scientist explains why these diseases pose unique R&D challenges and how researchers are beginning to overcome them.
Three Strikes, But Not Out Yet, Lilly’s Donanemab Approval Delayed Again
The US FDA wants to hold an advisory committee meeting for Lilly’s donanemab in early Alzheimer’s disease, which means approval will now occur after the expected Q1 decision date.
CTAD 2023: Medical Centers Adapt To Leqembi Testing, Monitoring Requirements
Neurologists shared their health care facilities’ protocols as they begin treating Alzheimer’s patients with the first anti-amyloid treatment to win both US FDA approval and Medicare coverage – Eisai/Biogen’s Leqembi.